Lipocine Inc.LPCNEarnings & Financial Report
Lipocine Inc is a clinical-stage biopharmaceutical company specializing in the development of hormone-based therapies. Its core product pipeline targets unmet medical needs in men's health, women's health, and liver disease, with primary operations and market focus in the United States. It prioritizes oral formulation innovation to improve patient treatment accessibility and adherence.
Revenue
$7.6M
Gross Profit
N/A
Operating Profit
$3.2M
Net Profit
$3.5M
Gross Margin
N/A
Operating Margin
42.3%
Net Margin
46.1%
YoY Growth
13751.9%
EPS
$0.66
Lipocine Inc. Q1 FY2024 Financial Summary
Lipocine Inc. reported revenue of $7.6M (up 13751.9% YoY) for Q1 FY2024, with a net profit of $3.5M (up 190.8% YoY) (46.1% margin).
Key Financial Metrics
| Total Revenue | $7.6M |
|---|---|
| Net Profit | $3.5M |
| Gross Margin | N/A |
| Operating Margin | 42.3% |
| Report Period | Q1 FY2024 |
Lipocine Inc. Quarterly Revenue & Net Profit History
Lipocine Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.1M | -67.2% | N/A | N/A |
| Q3 FY2024 | $0 | — | $-2.2M | N/A |
| Q1 FY2024 | $7.6M | +13751.9% | $3.5M | 46.1% |
Income Statement
| Q1 2024 | Q3 2024 | Q4 2025 | |
|---|---|---|---|
| Revenue | $7.6M | $0 | $1.1M |
| YoY Growth | 13751.9% | N/A | -67.2% |
Balance Sheet
| Q1 2024 | Q3 2024 | Q4 2025 | |
|---|---|---|---|
| Assets | $25.4M | $20.7M | $17.0M |
| Liabilities | $1.5M | $1.6M | $2.5M |
| Equity | $24.0M | $19.1M | $14.5M |
Cash Flow
| Q1 2024 | Q3 2024 | Q4 2025 | |
|---|---|---|---|
| Operating CF | $2.4M | $-2.8M | $-9.8M |